ï»¿Aarkstore - Migraine-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
Migraine-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Migraine. A key objective of DelveInsights report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Migraine. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Migraine. While the leading brands, companies and ...view middle of the document...
A review of the marketed products under prescription for Migraine, regulatory information and marketing status.
Coverage of global patent coverage and detailed commentaries on the US patent challenges.
Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
Product profiles for marketed products for Migraine with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
Coverage of API Manufacturers for Migraine drugs in the United States, Europe and Asian Regions with location details.
Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Migraine drugs.
Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Migraine drugs.
Coverage of Migraine Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
Key discontinued Marketed products.
Global Sales Figure from 2012-2016.
Reasons to buy
Evaluate the marketing status and exclusivity details of Migraine key products to exploit opportunities for generic drug development opportunities.
Identify and understand important and diverse types of therapeutics under Phase III development for Migraine.
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Migraine.
API intelligence over marketed drugs for Migraine and gaining primary intelligence over active ingredients manufacturers across the globe.
API intelligence over leading Phase III Pipeline drugs.
Develop and design strategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
Understanding the scope of the Phase III Drugs with nil regulatory filings.
Understanding the chemical route of synthesis of approved drugs for Migraine.
Uncovering opportunities in the rapidly growing US market.
Browse complete Report on:
Table of Content
Marketed Details of Drugs by Application Type
Marketed Details of Drugs (NDA) by Marketing Status
Marketed Details of Drugs by Patent Expiration Timeline
Active Pharmaceutical Ingredient (API) Manufacturers Assessment
API Manufacturers by United States Drug Master File (US DMF) Status
API Manufacturers by US DMF Status (Drug Specific)
API Manufacturers in Europe by Country
API Manufacturers in India by State
API Manufacturers in China by Province
Marketed Details of Approved Drugs by Geography
Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs